Wells Fargo’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-22,363
| Closed | -$4.94M | – | 7218 |
|
|
2025
Q4 | $4.94M | Buy |
22,363
+9,774
| +78% | +$1.58M | ﹤0.01% | 2696 |
|
|
2025
Q3 | $1.21M | Buy |
12,589
+1,797
| +17% | +$115K | ﹤0.01% | 3678 |
|
|
2025
Q2 | $526K | Buy |
+10,792
| New | +$259K | ﹤0.01% | 4103 |
|
|
2024
Q2 | – | Sell |
-32
| Closed | -$592 | – | 6973 |
|
|
2024
Q1 | $592 | Hold |
32
| – | – | ﹤0.01% | 6250 |
|
|
2023
Q4 | $503 | Buy |
32
+2
| +7% | +$32 | ﹤0.01% | 6379 |
|
|
2023
Q3 | $564 | Buy |
30
+1
| +3% | +$20 | ﹤0.01% | 6339 |
|
|
2023
Q2 | $645 | Buy |
29
+7
| +32% | +$165 | ﹤0.01% | 6433 |
|
|
2023
Q1 | $554 | Buy |
22
+1
| +5% | +$28 | ﹤0.01% | 6529 |
|
|
2022
Q4 | $324 | Buy |
21
+1
| +5% | +$12 | ﹤0.01% | 6493 |
|
|
2022
Q3 | $0 | Hold |
20
| – | – | ﹤0.01% | 6708 |
|
|
2022
Q2 | $0 | Buy |
20
+2
| +11% | +$25 | ﹤0.01% | 6848 |
|
|
2022
Q1 | $0 | Hold |
18
| – | – | ﹤0.01% | 7104 |
|
|
2021
Q4 | $0 | Buy |
18
+6
| +50% | +$187 | ﹤0.01% | 7255 |
|
|
2021
Q3 | $1K | Sell |
12
-2
| -14% | -$76 | ﹤0.01% | 6668 |
|
|
2021
Q2 | $1K | Sell |
14
-551
| -98% | -$23.3K | ﹤0.01% | 6627 |
|
|
2021
Q1 | $30K | Sell |
565
-3,199
| -85% | -$158K | ﹤0.01% | 6028 |
|
|
2020
Q4 | $150K | Sell |
3,764
-942
| -20% | -$46.8K | ﹤0.01% | 5201 |
|
|
2020
Q3 | $268K | Buy |
4,706
+1,635
| +53% | +$115K | ﹤0.01% | 4785 |
|
|
2020
Q2 | $227K | Buy |
3,071
+2,987
| +3,556% | +$194K | ﹤0.01% | 4830 |
|
|
2020
Q1 | $4K | Buy |
+84
| New | +$5.03K | ﹤0.01% | 5883 |
|
|
2019
Q1 | – | Sell |
-25
| Closed | -$1K | – | 6069 |
|
|
2018
Q4 | $1K | Hold |
25
| – | – | ﹤0.01% | 6259 |
|
|
2018
Q3 | $2K | Hold |
25
| – | – | ﹤0.01% | 6220 |
|
|
2018
Q2 | $3K | Buy |
+25
| New | +$2.36K | ﹤0.01% | 6135 |
|
|
2017
Q2 | – | Sell |
-451
| Closed | -$70K | – | 6233 |
|
|
2017
Q1 | $70K | Hold |
451
| – | – | ﹤0.01% | 5341 |
|
|
2016
Q4 | $94K | Buy |
451
+201
| +80% | +$41.8K | ﹤0.01% | 5177 |
|
|
2016
Q3 | $57K | Hold |
250
| – | – | ﹤0.01% | 5233 |
|
|
2016
Q2 | $52K | Buy |
250
+232
| +1,289% | +$56.2K | ﹤0.01% | 5186 |
|
|
2016
Q1 | $4K | Buy |
18
+17
| +1,700% | +$3.92K | ﹤0.01% | 5897 |
|
|
2015
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 6233 |
|
|
2015
Q3 | $0 | Sell |
1
-11
| -92% | -$3.15K | ﹤0.01% | 6218 |
|
|
2015
Q2 | $3K | Buy |
+12
| New | +$3.69K | ﹤0.01% | 6092 |
|
Wells Fargo's CDTX Position: Q1 2026 in Review
Wells Fargo sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 22,363 shares — an estimated $4.94M sold.
Wells Fargo first reported a position in CDTX in Q2 2015 and held it in 31 quarters. The position peaked at $4.94M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Wells Fargo reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Wells Fargo sold 22,363 Cidara Therapeutics shares in Q1 2026, an estimated $4.94M.
- Wells Fargo first reported a position in Cidara Therapeutics in Q2 2015 and held it in 31 quarters.
- Wells Fargo's Cidara Therapeutics position peaked at $4.94M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.